Nu Skin is presented as a deep-value turnaround with low valuation and Asian growth catalysts.
NUS — LONG Author argues NUS is deep value at sub-5x trailing and sub-7x forward earnings, with revenue growth in Latin America, China, and South Korea, and expansion in Asia aided by the $250M sale of its affiliate platform. Margin expansion, share repurchases, and a new subscription platform launched earlier this month are expected to drive continued growth into 2026. Peers trade at 15-25x forward earnings, supporting a re-rating opportunity.
Personal care peers trade 15-25x forward earnings; $NUS at sub-7x forward with superior cash generation and lower leverage post-divestiture.